These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 15519609

  • 1. Toxicology of antisense therapeutics.
    Jason TL, Koropatnick J, Berg RW.
    Toxicol Appl Pharmacol; 2004 Nov 15; 201(1):66-83. PubMed ID: 15519609
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Antisense applications for biological control.
    Pan WH, Clawson GA.
    J Cell Biochem; 2006 May 01; 98(1):14-35. PubMed ID: 16440307
    [Abstract] [Full Text] [Related]

  • 4. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT, Parkinson DR.
    Semin Oncol; 1997 Apr 01; 24(2):187-202. PubMed ID: 9129689
    [Abstract] [Full Text] [Related]

  • 5. Making sense of antisense.
    Vidal L, Blagden S, Attard G, de Bono J.
    Eur J Cancer; 2005 Dec 01; 41(18):2812-8. PubMed ID: 16289851
    [Abstract] [Full Text] [Related]

  • 6. Antisense oligonucleotide-based therapeutics for cancer.
    Dean NM, Bennett CF.
    Oncogene; 2003 Dec 08; 22(56):9087-96. PubMed ID: 14663487
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides.
    Sun Y, Duan M, Lin R, Wang D, Li C, Bo X, Wang S.
    Mol Vis; 2006 Nov 13; 12():1364-71. PubMed ID: 17149362
    [Abstract] [Full Text] [Related]

  • 9. Antisense oligonucleotide therapy in cancer.
    Stephens AC, Rivers RP.
    Curr Opin Mol Ther; 2003 Apr 13; 5(2):118-22. PubMed ID: 12772500
    [Abstract] [Full Text] [Related]

  • 10. Antisense treatments for biothreat agents.
    Warfield KL, Panchal RG, Aman MJ, Bavari S.
    Curr Opin Mol Ther; 2006 Apr 13; 8(2):93-103. PubMed ID: 16610760
    [Abstract] [Full Text] [Related]

  • 11. The role of antisense oligonucleotides in the treatment of bladder cancer.
    Duggan BJ, Gray S, Johnston SR, Williamson K, Miyaki H, Gleave M.
    Urol Res; 2002 Jul 13; 30(3):137-47. PubMed ID: 12111175
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The future of antisense therapy: combination with anticancer treatments.
    Biroccio A, Leonetti C, Zupi G.
    Oncogene; 2003 Sep 29; 22(42):6579-88. PubMed ID: 14528283
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers.
    Amantana A, Iversen PL.
    Curr Opin Pharmacol; 2005 Oct 29; 5(5):550-5. PubMed ID: 16087398
    [Abstract] [Full Text] [Related]

  • 16. Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.
    White PJ, Anastasopoulos F, Pouton CW, Boyd BJ.
    Expert Rev Mol Med; 2009 Mar 23; 11():e10. PubMed ID: 19302730
    [Abstract] [Full Text] [Related]

  • 17. RNAi: a novel antisense technology and its therapeutic potential.
    Dallas A, Vlassov AV.
    Med Sci Monit; 2006 Apr 23; 12(4):RA67-74. PubMed ID: 16572063
    [Abstract] [Full Text] [Related]

  • 18. An overview of sugar-modified oligonucleotides for antisense therapeutics.
    Prakash TP.
    Chem Biodivers; 2011 Sep 23; 8(9):1616-41. PubMed ID: 21922654
    [Abstract] [Full Text] [Related]

  • 19. Apoptosis, Bcl-2 antisense, and cancer therapy.
    Piro LD.
    Oncology (Williston Park); 2004 Nov 23; 18(13 Suppl 10):5-10. PubMed ID: 15651171
    [Abstract] [Full Text] [Related]

  • 20. In vitro toxicology and pharmacokinetics of antisense oligonucleotides.
    Crooke RM.
    Anticancer Drug Des; 1991 Dec 23; 6(6):609-46. PubMed ID: 1772572
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.